论文部分内容阅读
泰洛龙(Tilorone)处于临床前期试验,化学成份为7-双-2(二乙胺基)-芴醇-9-酮,动物试验证明其具有能保护小鼠免受致死性病毒及葡萄球菌感染,刺激吞噬反应,增生19S 抗体,并可使肿瘤缩小,不抑制骨髓功能的效用。在Ⅰ期试验中,泰洛龙在2例过去未用化疗的转移的黑色素瘤病人中应用,产生了一定效果。在10例用2周或更长时
Tilorone is in a preclinical trial with chemical composition 7-bis-2(diethylamino)-decanol-9-one. Animal tests have shown that it protects mice from lethal viruses and staphylococci. Infection, stimulation of phagocytosis, proliferation of 19S antibodies, and tumor shrinkage, does not inhibit the effectiveness of bone marrow function. In Phase I trials, talonol was used in 2 patients with metastatic melanoma who had not been treated with chemotherapy in the past and had a certain effect. When 10 patients use 2 weeks or longer